Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.

[1]  S. Moreno,et al.  Bone mineral density decline according to renal tubular dysfunction and phosphaturia in tenofovir-exposed HIV-infected patients , 2016, AIDS.

[2]  Sheena McCormack,et al.  Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial , 2016, The Lancet.

[3]  David Thompson,et al.  On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. , 2015, The New England journal of medicine.

[4]  J. Eron,et al.  Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. , 2015, The Lancet. Infectious diseases.

[5]  Douglas J. Taylor,et al.  Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women , 2015, AIDS.

[6]  D. Ho,et al.  A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge , 2015, Science Translational Medicine.

[7]  W. Heneine,et al.  The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge , 2015, Science Translational Medicine.

[8]  Douglas J. Taylor,et al.  Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial , 2014, BMC Pharmacology and Toxicology.

[9]  S. Piscitelli,et al.  Pharmacokinetics, Safety, and Tolerability With Repeat Doses of GSK1265744 and Rilpivirine (TMC278) Long-Acting Nanosuspensions in Healthy Adults , 2014, Journal of acquired immune deficiency syndromes.

[10]  S. Piscitelli,et al.  GSK1265744 Pharmacokinetics in Plasma and Tissue After Single-Dose Long-Acting Injectable Administration in Healthy Subjects , 2014, Journal of acquired immune deficiency syndromes.

[11]  D. Ho,et al.  Long-Acting Integrase Inhibitor Protects Macaques from Intrarectal Simian/Human Immunodeficiency Virus , 2014, Science.

[12]  W. Spreen,et al.  Long-acting injectable antiretrovirals for HIV treatment and prevention , 2013, Current opinion in HIV and AIDS.

[13]  S. Piscitelli,et al.  Pharmacokinetics, Safety, and Monotherapy Antiviral Activity of GSK1265744, an HIV Integrase Strand Transfer Inhibitor , 2013, HIV clinical trials.

[14]  S. Piscitelli,et al.  Lack of Pharmacokinetic Interaction between Rilpivirine and Integrase Inhibitors Dolutegravir and GSK1265744 , 2013, Antimicrobial Agents and Chemotherapy.

[15]  Katrien Fransen,et al.  Preexposure prophylaxis for HIV infection among African women. , 2012, The New England journal of medicine.

[16]  J. Stockman,et al.  Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men , 2012 .

[17]  V. Soriano,et al.  Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir , 2009, AIDS.